Jordan Clark | Authors

Articles

Discussing Reimbursement Barriers for FLT3 Mutation Analysis

July 11, 2019

FLT3 mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to Targeted Oncology about the cause of reimbursement issues and how the problem affects all parties involved.